European Heart Journal Advance Access published online on October 4, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi492
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Cardiology, Department of Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
* To whom correspondence should be addressed. Aims To elucidate the cellular mechanisms of cardioprotection of Methods and results We examined the gene expression before and 4 months after the administration of a Conclusion
Received January 3, 2005
Revised August 10, 2005
Accepted August 18, 2005
Clinical research
Increased gene expression of collagen Types I and III is inhibited by
-receptor blockade in patients with dilated cardiomyopathy
2 Division of Biotechnology, National Cardiovascular Center Research Institute, Osaka, Japan
3 Division of Radiology, National Cardiovascular Center, Osaka, Japan
4 Department of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
Masafumi Kitakaze, E-mail: kitakaze{at}hsp.ncvc.go.jp
![]()
Abstract
-blockers in patients with heart failure, we investigated the effects of
-blockers on collagen synthesis in patients with dilated cardiomyopathy (DCM).
-blocker in 17 DCM patients. The messenger ribonucleic acid expression of collagen Types I and III (Col I and III) and transforming growth factor-
1 (TGF-
1) of right ventricular tissues obtained by the endomyocardial biopsy were assessed by quantitative reverse transcriptase-polymerase chain reaction. Cardiac sympathetic nerve activity was assessed by the washout rate (WR) of 123I-metaiodobenzylguanidine from the heart. Left ventricular ejection fraction (21 ± 7 vs. 35 ± 9%) and WR (53 ± 14 vs. 42 ± 13%) improved significantly. Before the
-blocker treatment, the expressions of both Col I (r = 0.560, P = 0.041) and Col III (r = 0.630, P = 0.008) genes were correlated with WR. The expression levels of both Col I (1.08 ± 0.72 vs. 0.65 ± 0.26, P = 0.024) and Col III (2.06 ± 1.81 vs. 1.05 ± 0.74, P = 0.018) were reduced by a
-blocker. Changes in TGF-
1 correlated with those in WR (r = 0.606, P = 0.002).
-Blockers are considered to inhibit the expression of collagen-related genes in DCM, which seems to be mediated by TGF-
1.
-Blocker; Myocardial gene expression; Heart failure; Dilated cardiomyopathy.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. Matt, F. Schoenhoff, J. Habashi, T. Holm, C. Van Erp, D. Loch, O. D. Carlson, B. F. Griswold, Q. Fu, J. De Backer, et al. Circulating Transforming Growth Factor-{beta} in Marfan Syndrome Circulation, August 11, 2009; 120(6): 526 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Gavira, M. Perez-Ilzarbe, G. Abizanda, A. Garcia-Rodriguez, J. Orbe, J. A. Paramo, M. Belzunce, G. Rabago, J. Barba, J. Herreros, et al. A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction Cardiovasc Res, September 1, 2006; 71(4): 744 - 753. [Abstract] [Full Text] [PDF] |
||||

